Advertisement

Topics

Ocera Therapeutics, Inc. Company Profile

07:54 EST 23rd November 2017 | BioPortfolio

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic liver diseases and a broad range of gastrointestinal disorders. In addition to AST-120, Ocera is developing OCR-002, an ammonia detoxification agent, for the treatment of hospitalized patients with acute hepatic encephalopathy and acute liver failure. Ocera has raised $62.5 million dollars in venture financing from Domain Associates, Sofinnova Ventures, Thomas, McNerney & Partners, Montagu Newhall and InterWest Partners. Additional information on the company can be found at www.oceratherapeutics.com.


News Articles [537 Associated News Articles listed on BioPortfolio]

Mallinckrodt to Acquire Ocera Therapeutics for up to $117 Million

STAINES-UPON-THAMES, United Kingdom, and REDWOOD CITY, Calif., Nov. 2, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and Ocera Therapeutics...

Ocera Therapeutics: Übernahmeangebot mit CVRs - spannende Rendite bei überschaubarem Risiko

Das Unternehmen Ocera Therapeutics (NASDAQ: OCRX) ist ein Unternehmen aus der Branche Biotechnologie und hat aktuell nur einen Wirkstoff in der Pipeline - OCR-002 zur Behandlung von https://de.wiki...

Mallinckrodt buys Ocera

Mallinckrodt PLC is acquiring US-based Ocera Therapeutics Inc., a publicly-traded firm developing a treatment for hepatic encephalopathy (HE).

BRIEF—Mallinckrodt to acquire Ocera Therapeutics

US specialty drugmaker Mallinckrodt has entered into an agreement to acquire Ocera Therapeutics, a clinical…

Mallinckrodt to Acquire Ocera Therapeutics for Up to $117M

Mallinckrodt has agreed to acquire Ocera Therapeutics for up to $117 million, the companies said today, in a deal that would boost the buyer’s pipeline in treatments for orphan and other liver and k...

Ocera purchased by Mallinckrodt for up to $117M

Mallinckrodt will boost its pipeline in treatments for orphan and other kidney and liver and diseases after acquiring Ocera T -More- 

Ocera Therapeutics: When A Drug Fails, But Actually Works

Ocera Therapeutics Reports Second Quarter 2017 Financial Results

  Life Sciences Jobs   ...

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1169 Associated Companies listed on BioPortfolio]

Ocera Therapeutics, Inc.

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chro...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Ocera Therapeutics, Inc." on BioPortfolio

We have published hundreds of Ocera Therapeutics, Inc. news stories on BioPortfolio along with dozens of Ocera Therapeutics, Inc. Clinical Trials and PubMed Articles about Ocera Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ocera Therapeutics, Inc. Companies in our database. You can also find out about relevant Ocera Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...


Corporate Database Quicklinks



Searches Linking to this Company Record